


# 2021 NICE & GREEN YEAR IN REVIEW



Provided  
**CHF 100M in  
funding** to  
listed SMEs




**+73% of funding provided  
compared to 2020**, hence  
reflecting the greater demand of  
SMEs for Nice & Green's flexible  
and cost-efficient financing  
solutions




**Expanded  
our reach to  
Austria and  
the UK,**  
counting to 8  
countries in  
Europe



Entered new investment partnerships with 7 SMEs to fund their growth



Became the  
**largest**  
**shareholder**  
**of Napster**  
**Group**



Our significant rise in stake in Napster Group PLC, accounting for 16.5% of the share capital, **lies in the strategic and long-term partnership that we strive to build with our clients.**



**Participated  
in the IPO** of  
the French  
Biotech MaaT  
Pharma



The IPO transaction that raised €31.5M from institutional and private investors, allowed MaaT Pharma to be the **first microbiome company in Continental Europe to be trading on Euronext Paris.**



Joined **Swiss  
Biotech &  
France  
Biotech**  
Associations



Biotechs are playing a major role in improving the health of people around the world.

At Nice & Green, **we are determined to remain close to our peers in the Biotech ecosystem** and actively support the advancement of this sector.



Onboarded the  
Swiss **Artemis  
Group** as a new  
shareholder of  
Nice & Green



The Artemis Group, owned by Swiss entrepreneur Michael Pieper, has embraced Nice & Green's growth vision. **With the new capital raised, we are eager to better meet the evolving financing needs** of listed SMEs across Europe.





Welcomed  
**new  
ambitious  
talents** to  
our team



All of us joining forces to  
**improve listed SMEs' access to  
diversified and efficient  
Equity Financing solutions** and  
help them achieve growth



Follow us on LinkedIn  
for more news from Nice & Green

